Experimental toxoplasmosis in Balb/c mice. Prevention of vertical disease transmission by treatment and reproductive failure in chronic infection

In a study of congenital transmission during acute infection of Toxoplasma gondii, 23 pregnant Balb/c mice were inoculated orally with two cysts each of the P strain. Eight mice were inoculated 6-11 days after becoming pregnant (Group 1). Eight mice inoculated on the 10th-15th day of pregnancy (Group 2) were treated with 100 mg/kg/day of minocycline 48 h after inoculation. Seven mice inoculated on the 10th-15th day of pregnancy were not treated and served as a control (Group 3). Congenital transmission was evaluated through direct examination of the brains of the pups or by bioassay and serologic tests. Congenital transmission was observed in 20 (60.6%) of the 33 pups of Group 1, in one (3.6%) of the 28 pups of Group 2, and in 13 (54.2%) of the 24 pups of Group 3. Forty-nine Balb/c mice were examined in the study of congenital transmission of T. gondii during chronic infection. The females showed reproductive problems during this phase of infection. It was observed accentuated hypertrophy of the endometrium and myometrium. Only two of the females gave birth. Our results demonstrate that Balb/c mice with acute toxoplasmosis can be used as a model for studies of congenital T. gondii infection. Our observations indicate the potential of this model for testing new chemotherapeutic agents against congenital toxoplasmosis.

Adjuvant or radical fractionated stereotactic radiotherapy for patients with pituitary functional and nonfunctional macroadenoma.

Purpose: To evaluate the efficacy and toxicity of stereotactic fractionated radiotherapy (SFRT) for patients with pituitary macroadenoma (PMA).Methods and Materials: Between March 2000 and March 2009, 27 patients (male to female ratio, 1.25) with PMA underwent SFRT (median dose, 50.4 Gy). Mean age of the patients was 56.5 years (range, 20.3 - 77.4). In all but one patient, SFRT was administered for salvage treatment after surgical resection (transphenoidal resection in 23, transphenoidal resection followed by craniotomy in 2 and multiple transphenoidal resections in another patient). In 10 (37%) patients, the PMAs were functional (3 ACTH-secreting, 3 prolactinomas, 2 growth hormone-secreting and 2 multiple hormone-secretion). Three (11.1%) and 9 (33.3%) patients had PMA abutting and compressing the optic chiasm, respectively. Mean tumor volume was 2.9 +/- 4.6 cm(3). Eighteen (66.7%) patients had hypopituitarism prior to SFRT. The mean follow-up period after SFRT was 72.4 +/- 37.2 months.Results: Tumor size decreased for 6 (22.2%) patients and remained unchanged for 19 (70.4%) other patients. Two (7.4%) patients had tumor growth inside the prescribed treatment volume. The estimated 5-year tumor growth control was 95.5% after SFRT. Biochemical remission occurred in 3 (30%) patients with functional PMA. Two patients with normal anterior pituitary function before SFRT developed new deficits 25 and 65 months after treatment. The 5-year survival without new anterior pituitary deficit was thus 95.8%. Five patients with visual field defect had improved visual function and 1 patient with no visual defect prior to SFRT, but an optic chiasm abutting tumor, had a decline in visual function. The estimated 5-year vision and pituitary function preservation rates were 93.2% and 95.8%, respectively.Conclusions: SFRT is a safe and effective treatment for patients with PMA, although longer follow-up is needed to evaluate long-term outcomes. In this study, approximately 1 patient with visual field defect out of two had an improved visual.

Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death.

BACKGROUND: Subclinical hypothyroidism has been associated with systolic and diastolic cardiac dysfunction and an elevated cholesterol level, but data on cardiovascular outcomes and death are limited. METHODS: We studied 2730 men and women, aged 70 to 79 years, with baseline thyrotropin (TSH) measurements and 4-year follow-up data to determine whether subclinical hypothyroidism was associated with congestive heart failure (CHF), coronary heart disease, stroke, peripheral arterial disease, and cardiovascular-related and total mortality. After the exclusion of participants with abnormal thyroxine levels, subclinical hypothyroidism was defined as a TSH level of 4.5 mIU/L or greater, and was further classified according to TSH levels (4.5-6.9, 7.0-9.9, and > or = 10.0 mIU/L). RESULTS: Subclinical hypothyroidism was present in 338 (12.4%) of the participants. Compared with euthyroid participants, CHF events occurred more frequently among those with a TSH level of 7.0 mIU/L or greater (35.0 vs 16.5 per 1000 person-years; P = .006), but not among those with TSH levels between 4.5 and 6.9 mIU/L. In multivariate analyses, the risk of CHF was higher among those with high TSH levels (TSH of 7.0-9.9 mIU/L: hazard ratio, 2.58 [95% confidence interval, 1.19-5.60]; and TSH of > or = 10.0 mIU/L: hazard ratio, 3.26 [95% confidence interval, 1.37-7.77]). Among the 2555 participants without CHF at baseline, the hazard ratio for incident CHF events was 2.33 (95% confidence interval, 1.10-4.96; P = .03) in those with a TSH of 7.0 mIU/L or greater. Subclinical hypothyroidism was not associated with increased risk for coronary heart disease, stroke, peripheral arterial disease, or cardiovascular-related or total mortality. CONCLUSIONS: Subclinical hypothyroidism is associated with an increased risk of CHF among older adults with a TSH level of 7.0 mIU/L or greater, but not with other cardiovascular events and mortality. Further investigation is warranted to assess whether subclinical hypothyroidism causes or worsens preexisting heart failure.

Subclinical hypothyroidism and the risk of coronary heart disease and mortality.

CONTEXT: Data regarding the association between subclinical hypothyroidism and cardiovascular disease outcomes are conflicting among large prospective cohort studies. This might reflect differences in participants' age, sex, thyroid-stimulating hormone (TSH) levels, or preexisting cardiovascular disease. OBJECTIVE: To assess the risks of coronary heart disease (CHD) and total mortality for adults with subclinical hypothyroidism. DATA SOURCES AND STUDY SELECTION: The databases of MEDLINE and EMBASE (1950 to May 31, 2010) were searched without language restrictions for prospective cohort studies with baseline thyroid function and subsequent CHD events, CHD mortality, and total mortality. The reference lists of retrieved articles also were searched. DATA EXTRACTION: Individual data on 55,287 participants with 542,494 person-years of follow-up between 1972 and 2007 were supplied from 11 prospective cohorts in the United States, Europe, Australia, Brazil, and Japan. The risk of CHD events was examined in 25,977 participants from 7 cohorts with available data. Euthyroidism was defined as a TSH level of 0.50 to 4.49 mIU/L. Subclinical hypothyroidism was defined as a TSH level of 4.5 to 19.9 mIU/L with normal thyroxine concentrations. RESULTS: Among 55,287 adults, 3450 had subclinical hypothyroidism (6.2%) and 51,837 had euthyroidism. During follow-up, 9664 participants died (2168 of CHD), and 4470 participants had CHD events (among 7 studies). The risk of CHD events and CHD mortality increased with higher TSH concentrations. In age- and sex-adjusted analyses, the hazard ratio (HR) for CHD events was 1.00 (95% confidence interval [CI], 0.86-1.18) for a TSH level of 4.5 to 6.9 mIU/L (20.3 vs 20.3/1000 person-years for participants with euthyroidism), 1.17 (95% CI, 0.96-1.43) for a TSH level of 7.0 to 9.9 mIU/L (23.8/1000 person-years), and 1.89 (95% CI, 1.28-2.80) for a TSH level of 10 to 19.9 mIU/L (n = 70 events/235; 38.4/1000 person-years; P <.001 for trend). The corresponding HRs for CHD mortality were 1.09 (95% CI, 0.91-1.30; 5.3 vs 4.9/1000 person-years for participants with euthyroidism), 1.42 (95% CI, 1.03-1.95; 6.9/1000 person-years), and 1.58 (95% CI, 1.10-2.27, n = 28 deaths/333; 7.7/1000 person-years; P = .005 for trend). Total mortality was not increased among participants with subclinical hypothyroidism. Results were similar after further adjustment for traditional cardiovascular risk factors. Risks did not significantly differ by age, sex, or preexisting cardiovascular disease. CONCLUSIONS: Subclinical hypothyroidism is associated with an increased risk of CHD events and CHD mortality in those with higher TSH levels, particularly in those with a TSH concentration of 10 mIU/L or greater.

Étude des biais sur la dose parentérale d'un nouveau médicament lors d'un essai clinique avec profil cinétique.

Introduction et objectif: Lors d'essais cliniques, le pharmacien est responsable de la préparation et de la dispensation des médicaments à évaluer. Un article récent a toutefois montré que les aspects pharmaceutiques liés au contrôle de la dose administrée in fine étaient souvent mal contrôlés. Il peut exister une différence entre la dose nominale fournie par le certificat d'analyse du fabricant et la dose réellement administrée au sujet, biais qui se reporte en cascade sur l'estimation des paramètres pharmaco¬cinétiques (PK), comme la clairance ou le volume de distribution. Ce travail visait à évaluer les biais entachant la quantité de médicament réellement injectée (iv/sc) aux volontaires d'un essai clinique étudiant la PK et la relation dose-réponse d'un nouveau produit biotechnologique. Méthode: La dose de médicament administrée lors de l'essai clinique (D) a été calculée de la manière suivante: D = C ? V - pertes. La concentration du produit (C; titre nominal du fabricant) a été vérifiée par immuno-essai. Le volume de médicament injecté (V) a été déterminé pour chaque injection par pesée (n=72), en utilisant la masse de la seringue avant et après injection et la densité du produit. Enfin, une analyse in vitro a permis d'évaluer les pertes liées à l'adsorption du produit dans les lignes de perfusion et de choisir le dispositif adéquat in vivo. Résultats: La concentration du médicament s'est révélée proche du titre nominal (96 ± 7%), et a été utilisée comme référence. Le volume injecté était quant à lui entaché d'un biais systématique par rapport à la valeur théorique correspondant à 0.03 mL pour la dose minimale (i.e. 75% du volume à injecter à cette dose). Une analyse complémentaire a montré que cela s'expliquait par une réaspiration partielle de la solution médica-menteuse avant le retrait de la seringue après injection sc, due à l'élasticité du piston. En iv, le biais était par contre provoqué par une réaspiration du soluté de perfusion co-administré. Enfin, la mesure des quantités de médicament récupérées après injection dans le dispositif de perfusion a démontré des pertes minimales par adsorption. Discussion-conclusion: Cette étude confirme l'existence de biais inversement corrélés au volume et à la concentration du médicament administré, pouvant provoquer des erreurs importantes sur les paramètres PK. Ce problème est négligé ou insuffisamment considéré dans les protocoles de Phase I et nécessiterait une planification rigoureuse. Les procédures opératoires devraient attirer l'attention sur ce point crucial.

Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts.

BACKGROUND: American College of Cardiology/American Heart Association guidelines for the diagnosis and management of heart failure recommend investigating exacerbating conditions such as thyroid dysfunction, but without specifying the impact of different thyroid-stimulation hormone (TSH) levels. Limited prospective data exist on the association between subclinical thyroid dysfunction and heart failure events. METHODS AND RESULTS: We performed a pooled analysis of individual participant data using all available prospective cohorts with thyroid function tests and subsequent follow-up of heart failure events. Individual data on 25 390 participants with 216 248 person-years of follow-up were supplied from 6 prospective cohorts in the United States and Europe. Euthyroidism was defined as TSH of 0.45 to 4.49 mIU/L, subclinical hypothyroidism as TSH of 4.5 to 19.9 mIU/L, and subclinical hyperthyroidism as TSH <0.45 mIU/L, the last two with normal free thyroxine levels. Among 25 390 participants, 2068 (8.1%) had subclinical hypothyroidism and 648 (2.6%) had subclinical hyperthyroidism. In age- and sex-adjusted analyses, risks of heart failure events were increased with both higher and lower TSH levels (P for quadratic pattern <0.01); the hazard ratio was 1.01 (95% confidence interval, 0.81-1.26) for TSH of 4.5 to 6.9 mIU/L, 1.65 (95% confidence interval, 0.84-3.23) for TSH of 7.0 to 9.9 mIU/L, 1.86 (95% confidence interval, 1.27-2.72) for TSH of 10.0 to 19.9 mIU/L (P for trend <0.01) and 1.31 (95% confidence interval, 0.88-1.95) for TSH of 0.10 to 0.44 mIU/L and 1.94 (95% confidence interval, 1.01-3.72) for TSH <0.10 mIU/L (P for trend=0.047). Risks remained similar after adjustment for cardiovascular risk factors. CONCLUSION: Risks of heart failure events were increased with both higher and lower TSH levels, particularly for TSH ≥10 and <0.10 mIU/L.

Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils.

PURPOSE: To analyze outcomes after right portal vein embolization extended to segment IV (right PVE + IV) before extended right hepatectomy, including liver hypertrophy, resection rates, and complications after embolization and resection, and to assess differences in outcomes with two different particulate embolic agents. MATERIALS AND METHODS: Between 1998 and 2004, transhepatic ipsilateral right PVE + IV with particles and coils was performed in 44 patients with malignant hepatobiliary disease, including metastases (n = 24), biliary cancer (n = 14), and hepatocellular carcinoma (n = 6). Right PVE + IV was considered if the future liver remnant (FLR; segments II/III with or without I) was less than 25% of the total estimated liver volume (TELV). Tris-acryl microspheres (100-700 microm; n = 21) or polyvinyl alcohol (PVA) particles (355-1,000 microm; n = 23) were administered in a stepwise fashion. Smaller particles were used to occlude distal branches, followed by larger particles to occlude proximal branches until near-complete stasis. Coils were then placed in secondary portal branches. Computed tomographic volumetry was performed before and 3-4 weeks after right PVE + IV to assess FLR hypertrophy. Liver volumes and postembolization and postoperative outcomes were measured. RESULTS: After right PVE + IV with PVA particles, FLR volume increased 45.5% +/- 40.9% and FLR/TELV ratio increased 6.9% +/- 5.6%. After right PVE + IV with tris-acryl microspheres, FLR volume increased 69.0% +/- 30.7% and FLR/TELV ratio increased 9.7% +/- 3.3%. Differences in FLR volume (P = .0011), FLR/TELV ratio (P = .027), and resection rates (P = .02) were statistically significant. Seventy-one percent of patients underwent extended right hepatectomy (86% after receiving tris-acryl microspheres, 57% after receiving PVA). Thirteen patients (29%) did not undergo resection (extrahepatic spread [n = 9], inadequate hypertrophy [n = 3], other reasons [n = 1]). No patient developed postembolization syndrome or progressive liver insufficiency after embolization or resection. One death after resection occurred as a result of sepsis and hemorrhage. Median hospital stays were 1 day after right PVE + IV and 7 days after resection. CONCLUSION: Transhepatic ipsilateral right PVE + IV with use of particles and coils is a safe, effective method for inducing contralateral hypertrophy before extended right hepatectomy. Embolization with small spherical particles provides improved hypertrophy and resection rates compared with larger, nonspherical particles.

Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study.

BACKGROUND: The race- and sex-specific epidemiology of incident heart failure (HF) among a contemporary elderly cohort are not well described. METHODS: We studied 2934 participants without HF enrolled in the Health, Aging, and Body Composition Study (mean [SD] age, 73.6 [2.9] years; 47.9% men; 58.6% white; and 41.4% black) and assessed the incidence of HF, population-attributable risk (PAR) of independent risk factors for HF, and outcomes of incident HF. RESULTS: During a median follow-up of 7.1 years, 258 participants (8.8%) developed HF (13.6 cases per 1000 person-years; 95% confidence interval, 12.1-15.4). Men and black participants were more likely to develop HF. No significant sex-based differences were observed in risk factors. Coronary heart disease (PAR, 23.9% for white participants and 29.5% for black participants) and uncontrolled blood pressure (PAR, 21.3% for white participants and 30.1% for black participants) carried the highest PAR in both races. Among black participants, 6 of 8 risk factors assessed (smoking, increased heart rate, coronary heart disease, left ventricular hypertrophy, uncontrolled blood pressure, and reduced glomerular filtration rate) had more than 5% higher PAR compared with that among white participants, leading to a higher overall proportion of HF attributable to modifiable risk factors in black participants vs white participants (67.8% vs 48.9%). Participants who developed HF had higher annual mortality (18.0% vs 2.7%). No racial difference in survival after HF was noted; however, rehospitalization rates were higher among black participants (62.1 vs 30.3 hospitalizations per 100 person-years, P < .001). CONCLUSIONS: Incident HF is common in older persons; a large proportion of HF risk is attributed to modifiable risk factors. Racial differences in risk factors for HF and in hospitalization rates after HF need to be considered in prevention and treatment efforts.

Resposta da soja e da biomassa de carbono do solo aos resíduos de cinco genótipos de sorgo

O trabalho teve como objetivo avaliar a influência de resíduos de cinco cultivares de sorgo (Sorghum bicolor L.): CMS XS 376, CMS XS 365, BR 304, BR 700 e CMS XS 755 no crescimento e no desenvolvimento da soja. Esses resíduos foram colhidos em três estádios do desenvolvimento reprodutivo do sorgo: florescimento, enchimento de grãos e maturação. Os tratamentos estudados constaram da deposição desses resíduos na superfície do solo ou da sua total incorporação na proporção de 4 g kg-1 de matéria seca no solo (LEd, fase cerrado). Nos tratamentos com planta, mantiveram-se três plantas de soja (cv. Doko) em vasos com capacidade para 3 kg de solo. Nos tratamentos sem planta, o solo foi amostrado semanalmente para avaliação das formas de N. Após a colheita da soja, amostras de planta e de solo, de cada tratamento, foram retiradas para determinar a absorção total de N e a influência desses resíduos no N disponível extraído com KCl 2 mol L-1. Os resultados revelaram que alguns resíduos culturais de sorgo afetaram, independentemente do estádio de colheita, o desenvolvimento da soja, a absorção de N, o peso de nódulos e a biomassa microbiana do solo. Tais efeitos também foram dependentes do método de incorporação do resíduo. O teor de carbono imobilizado pela biomassa foi maior quando os resíduos de sorgo foram distribuídos na superfície do solo.

Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.

Purpose: Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However, "endogenous" biotin can interfere with the effectiveness of this approach by blocking binding of radiolabeled biotin to SAv. We engineered a series of SAv FPs that downmodulate the affinity of SAv for biotin, while retaining high avidity for divalent DOTA-bis-biotin to circumvent this problem.Experimental Design: The single-chain variable region gene of the murine 1F5 anti-CD20 antibody was fused to the wild-type (WT) SAv gene and to mutant SAv genes, Y43A-SAv and S45A-SAv. FPs were expressed, purified, and compared in studies using athymic mice bearing Ramos lymphoma xenografts.Results: Biodistribution studies showed delivery of more radioactivity to tumors of mice pretargeted with mutant SAv FPs followed by (111)In-DOTA-bis-biotin [6.2 +/- 1.7% of the injected dose per gram (%ID/gm) of tumor 24 hours after Y43A-SAv FP and 5.6 +/- 2.2%ID/g with S45A-SAv FP] than in mice on normal diets pretargeted with WT-SAv FP (2.5 +/- 1.6%ID/g; P = 0.01). These superior biodistributions translated into superior antitumor efficacy in mice treated with mutant FPs and (90)Y-DOTA-bis-biotin [tumor volumes after 11 days: 237 +/- 66 mm(3) with Y43A-SAv, 543 +/- 320 mm(3) with S45A-SAv, 1129 +/- 322 mm(3) with WT-SAv, and 1435 +/- 212 mm(3) with control FP (P < 0.0001)].Conclusions: Genetically engineered mutant-SAv FPs and bis-biotin reagents provide an attractive alternative to current SAv-biotin PRIT methods in settings where endogenous biotin levels are high. Clin Cancer Res; 17(23); 7373-82. (C)2011 AACR.

Bulles de papes. Titres des maisons de LA JUGIE (1313-1623). — MELANGES (1222-1623).

Contient : Titres de la Jugie ; N° 623 (1) Contrat de mariage de Jacques de la Jugie et de Guillemette de la Borgayrie (23 juillet 1313) ; copie du 18 mars 1314 a. st ; N° 624 (2) Contrat de mariage de Pierre de la Jugie et de Jeanne Pebeyre (août1316) ; restes de sceau sur simple queue ; N° 625 (3) Testament de Geraud de Rajaut, de Tulle, damoiseau (9 août 1329) ; N° 626 (4) Contrat de mariage de Gui Aimoin de Puydeval et d'Hélie de la Jugie (14 décembre 1339) ; N° 627 (5) Donation de biens faite par Guillemette de la Limosnie à Gui de Puydeval, son oncle (30 janvier 1351) ; copie du XVIIe siècle ; N° 628 (6) Accord entre Archambaud, vicomte de Comborn, et Gui de Puydeval (24 mai 1351) ; copie contemporaine ; N° 629 (7) Contrat de mariage de Raimond de Bossac et de Marie de Puydeval (2 août 1352) ; N° 630 (8) Testament de Gui de Puydeval (26 janvier 1371 a. st.) ; copie du XVIIe siècle ; N° 631 (9) Testament de Nicolas de la Jugie, seigneur de Levinerie (26 mars 1374 a. st.) ; vidimus du 18 mai 1402 ; N° 632 (10) Testament de Guillaume de la Jugie, alias de Puydeval (20 août 1397) ; N° 633 (11) Testament d'Aelis de la Jugie (19 juillet 1409) ; N° 634 (12) Décisions prises par divers seigneurs du Limousin, relativement à l'expédition contre les Anglais, pour la levée du siège d'Auberoche (4 septembre 1419) ; N° 635 (13) Contrat de mariage d'Aimar de Puydeval et de Marguerite de Gimel (12 juillet 1426) ; N° 636 (14) Testament d'Hélène de Puydeval, veuve de Jean « de Sadone » (2 juin 1436) ; N° 637 (15) Testament de Jean de la Jugie, alias de Puydeval (7 décembre 1461) ; N° 638 (16) Contrat de mariage de Jean de Sourries, seigneur de Vaur, et d'Anne de Puydeval (29 janvier 1492 a. st.) ; copie, papier ; N° 639 (17) Testament d'Antoine de Puydeval (9 octobre 1495) ; copie du 28 mars 1502, a. st ; N° 640 (18) Contrat de mariage de Pons de Gourdon, seigneur de La Roque, et de Françoise de Puydeval (20 janvier 1497 a. st.) ; copie du 23 août 1579 ; N° 641 (19) Quittance générale donnée par Blanche de Malesec, veuve d'Antoine de Puydeval, à Gilles de Malesec, son frère (23 juin 1512) ; N° 642 (20) Testament de Gabrielle de Puydeval, dame de Miremont (20 mars 1516-1517) ; copie du XVIe siècle ; N° 643 (21) Testament de Denis de Puydeval (18 août 1523) ; copie du XVIe siècle ; N° 644 (22) Quittance générale donnée à Géraud de Puydeval par Pierre de Rajaut et Anne de Puydeval sa femme, 2 août 1534 ; N° 645 (23) Contrat de mariage de Rigaut de Saint-Martial, baron de Conros, et de Françoise de Puydeval (18 juin 1559) ; copie du 22 juillet 1583 ; N° 646 (24) Testament de Géraud de Puydeval (20 mai 1563) ; N° 647 (25) Procès-verbal de visite de bois faite par les arbitres choisis par les seigneurs de Puydeval et de Vaur (5 janvier 1564) ; N° 648 (26) Accord entre Géraud de Puydeval et Bonaventure de Sourries, seigneur de Vaur, au sujet du lieu de La Reynie (21 novembre 1560) ; N° 649 (27) Accord entre Anne de Puydeval, veuve de Jean de Sourries, seigneur de Vaur, et Bonaventure de Sourries (27 septembre 1559) ; N° 650 (28) Testament d'Anne de Puydeval, veuve de Jean [de Sourries, seigneur de] Vaur (8 septembre 1555) ; N° 651 (29) Testament de Jean de Puydeval, doyen de l'église de Tulle ; N° 652 (30) Testament de Françoise de Puydeval, veuve de Rigaut de Saint-Marsal, baron de Conros (16 juin 1601) ; N° 653 (31) Autre testament de ladite dame (22 août 1604) ; N° 654 Copie du précédent testament ; N° 655 (32) Accord entre Josias de Cosnac, seigneur d'Assy, et sa soeur, Marie de Cosnac, femme de Henry de Puydeval, baron de Conros (31 mars 1623 ; N° 656 (33) Contrat de mariage de Pierre de Soudeilles et d'Anne de Puydeval (s. d.) ; N° 657 (33 bis) Copie de la pièce précédente ; Mélanges ; N° 658 (1) Accord entre Guillaume, évêque de Paris, et son chapitre, d'une part, et Philippe-Auguste, de l'autre, au sujet des droits de l'église de Paris (décembre 1222) ; N° 659 (2) Accord entre Philippe le Bel et l'église de Paris pour l'affectation de certaines redevances à la réparation des ponts de la Seine (mars 1296-1297) ; N° 660 (3) Décret de l'Université de Paris établissant des règlements pour le collège de Narbonne, à Paris (4 octobre 1377) ; N° 661 (4) Sentence rendue par Jean, abbé de Saint-Taurin d'Evreux, sur le procès entre Jacques Sacquespée, docteur en médecine, et Jean Daigny, chanoine de la Sainte-Chapelle de Paris (15 mai 1428) ; N° 662 (15) Articles de la Ligue (s. d. [1586 (?)]) ; N° 663 (6) Privilèges accordés par Louis, comte de Flandre, aux marchands castillans trafiquant en Flandre (15 avril 1366) ; copie du XVe siècle ; N° 664 (7) Serment prêté au duc d'Alençon par le chapitre de Cambrai (20 août 1580) ; N° 665 (8) Serment prêté au même personnage par les échevins de la ville de Cambrai (même date) ; N° 666 (9) Aveu rendu à Henri, comte de Rodez, par Pierre de Panat, pour divers fiefs, (juillet 1280) ; N° 667 (10) Aveu rendu par Bernard, comte d'Armagnac et de Rodez, à Guillaume, évêque de Mende, pour les fiefs tenus par ledit comte dans ce diocèse (2 mai 1309) ; N° 668 (11) Autorisation donnée par l'archevêque Michel et le chapitre d'Arles à Jean [de Matha], fondateur de l'Ordre de la Trinité, d'établir une église et un cimetière dans la ville d'Arles (novembre 1203) ; N° 669 (12) Charte de G[uillaume], comte de Forcalquier, abandonnant divers droits à l'église de Ganagobie (10 juin 1206) ; à la suite est transcrite une lettre de A., prieur du dit lieu, à G[uillaume], abbé de Cluny, relative à la donation précédente ; N° 670 (13) Lettres de Charles II, roi de Sicile, comte de Provence, chargeant Hugues de Voisines, senéchal de Provence, de faire sortir du royaume de France la somme de 50.000 livres autorisée par le Roi (24 mars 1297) ; N° 671 (14) Lettres de l'empereur Henri VII, autorisant Gaillard, archevêque d'Arles, à poursuivre la révocation des aliénations de biens ecclésiastiques consenties par ses prédécesseurs (9 juillet 1312) ; N° 672 (15) Lettres de Jean de Clermont, cardinal-évêque de Tusculum, légat du pape dans les provinces de Vienne, Aix, etc., chargeant Jean Ferrier, archevêque d'Arles, de l'assister dans ses fonctions (9 juillet 1533) ; N° 673 (16) Lettres de Raoul de Sendelay, trésorier d'Angleterre, portant donation de terres près de Rouen à Michel de Paris, son ancien serviteur (3 janvier 1445-1446) ; N° 674 (17) Lettre de l'empereur Ferdinand au pape Urbain VIII (28 avril 1635) ; N° 675 (18) Aveu rendu à Bernard, abbé de Charroux, par Jean de Rochefort, pour le château de Saint-Angel (18 mai 1393) ; copie du 17 juillet 1407 ; N° 676 (19) Lettres de l'Université d'Avignon conférant à Pierre Charpin le titre de docteur en droit canon (16 septembre 1405) ; N° 677 (20) Contrat de mariage de Charles d'Apchon, vicomte de Mirmont, et de Lucrèce de Gadaigne (3 août 1579) ; N° 678 (21) Procuration donnée par Philippe de Commynes à Baude Talboein, son secrétaire (9 mars 1474) ; signature autographe ; N° 679 (22) Ratification par Galéas-Marie Sforza du traité conclu en son nom à Amboise entre Tristan Sforza et Louis XI (21 avril 1468) ; N° 680 (23) Lettres d'Etat accordées par le roi Charles VI à Lermite, seigneur de La Faye, son chambellan, envoyé en Angleterre (28 octobre 1407) ; copie du 4 novembre 1407 ; papier ; N° 681 (24) « Plaintes sur le trépas du sage et vertueux chevalier... Jean de La Roche-Aymon ; » pièce de vers (s. d. [1522]) ; miniature en tête ; N° 682 (25) Lettres de Raimond « de Poioliis », archidiacre de Périgueux, recteur du duché de Spolète, pour le paiement de la compagnie de Guillaume de Primat ; N° 683 (26) Lettres de l'Université d'Orléans accordant à Hugues Berthelot le titre de bachelier en droit canon (28 juillet 1409) ; N° 684 (27) Lettres de l'Université d'Orléans au prieur de Marcigny, pour faire pourvoir d'un bénéfice Raoul « Druci », prêtre, licencié en décret (2 septembre 1460 ; N° 685 (28) Lettres de l'Université de Paris à l'abbé de Cluny, pour faire pourvoir d'un bénéfice Jean de Mont, maître ès arts et bachelier en théologie (3 mars 1478-1479) ; N° 686 (29) Lettres de l'Université de Paris à l'abbé de Cluny pour faire pourvoir d'un bénéfice Jean Paulain, maître ès arts (21 février 1538-1539) ; N° 687 (30) Testament de Jacques de Plaigne, seigneur dudit lieu (5 mars 1551-1552) ; copie contemporaine ; N° 688 (31) Contrat de mariage de Pierre de Guasquet et de Marguerite d'Henry (31 mars 1581) ; copie contemporaine ; N° 689 (32) Testament d'Antoine de Guasquet, seigneur de Paramelle (30 août 1585) ; copie contemporaine ; N° 690 (33) Testament de Jean Chantois, sieur de Laumosnerie (30 septembre 1617) ; copie contemporaine ; N° 691 (34) Testament de Claude des Rozières, seigneur de Cherouac (octobre 1623) ; copie contemporaine ; N° 692 (35) Délibération de l'assemblée du clergé de la ville de Reims au sujet de la répartition des deniers à lever sur ledit clergé (30 mars 1585) ; N° 693 (36) Lettre de J[ean de] C[andida] à [Denis Briçonnet], évêque de Saint-Malo (16 novembre, s. d.)

Primary mucosa-associated lymphoid tissue lymphoma of the salivary glands: a multicenter Rare Cancer Network study.

Purpose: Involvement of salivary glands with mucosa-associated lymphoid tissue (MALT) lymphoma is rare. This retrospective study was performed to assess the clinical profile, treatment outcome, and prognostic factors of MALT lymphoma of the salivary glands.Methods and Materials: Thirteen member centers of the Rare Cancer Network from 10 countries participated, providing data on 63 patients. The median age was 58 years; 47 patients were female and 16 were male. The parotid glands were involved in 49 cases, submandibular in 15, and minor glands in 3. Multiple glands were involved in 9 patients. Staging was as follows: IE in 34, IIE in 12, IIIE in 2, and IV in 15 patients.Results: Surgery (S) alone was performed in 9, radiotherapy (RI) alone in 8, and chemotherapy (CT) alone in 4 patients. Forty-one patients received combined modality treatment (S + RT in 23, S + CT in 8, RT + CT in 4, and all three modalities in 6 patients). No active treatment was given in one case. After initial treatment there was no tumor in 57 patients and residual tumor in 5. Tumor progression was observed in 23 (36.5%) (local in 1, other salivary glands in 10, lymph nodes in 11, and elsewhere in 6). Five patients died of disease progression and the other 5 of other causes. The 5-year disease-free survival, disease-specific survival, and overall survival were 54.4%, 93.2%, and 81.7%, respectively. Factors influencing disease-free survival were use of RI, stage, and residual tumor (p < 0.01). Factors influencing disease-specific survival were stage, recurrence, and residual tumor (p < 0.01).Conclusions: To our knowledge, this report represents the largest series of MALT lymphomas of the salivary glands published to date. This disease may involve all salivary glands either initially or subsequently in 30% of patients. Recurrences may occur in up to 35% of patients at 5 years; however, survival is not affected. Radiotherapy is the only treatment modality that improves disease-free survival. (C) 2012 Elsevier Inc.

Low income, community poverty and risk of end stage renal disease

BACKGROUND: The risk of end stage renal disease (ESRD) is increased among individuals with low income and in low income communities. However, few studies have examined the relation of both individual and community socioeconomic status (SES) with incident ESRD. METHODS: Among 23,314 U.S. adults in the population-based Reasons for Geographic and Racial Differences in Stroke study, we assessed participant differences across geospatially-linked categories of county poverty [outlier poverty, extremely high poverty, very high poverty, high poverty, neither (reference), high affluence and outlier affluence]. Multivariable Cox proportional hazards models were used to examine associations of annual household income and geospatially-linked county poverty measures with incident ESRD, while accounting for death as a competing event using the Fine and Gray method. RESULTS: There were 158 ESRD cases during follow-up. Incident ESRD rates were 178.8 per 100,000 person-years (105 py) in high poverty outlier counties and were 76.3 /105 py in affluent outlier counties, p trend = 0.06. In unadjusted competing risk models, persons residing in high poverty outlier counties had higher incidence of ESRD (which was not statistically significant) when compared to those persons residing in counties with neither high poverty nor affluence [hazard ratio (HR) 1.54, 95% Confidence Interval (CI) 0.75-3.20]. This association was markedly attenuated following adjustment for socio-demographic factors (age, sex, race, education, and income); HR 0.96, 95% CI 0.46-2.00. However, in the same adjusted model, income was independently associated with risk of ESRD [HR 3.75, 95% CI 1.62-8.64, comparing the < $20,000 income group to the > $75,000 group]. There were no statistically significant associations of county measures of poverty with incident ESRD, and no evidence of effect modification. CONCLUSIONS: In contrast to annual family income, geospatially-linked measures of county poverty have little relation with risk of ESRD. Efforts to mitigate socioeconomic disparities in kidney disease may be best appropriated at the individual level.